Lupin on Monday said it had received approval from the U.K. health regulator for its Goa facility.
The facility was inspected by the United Kingdom’s Medicines and Healthcare products Regulatory Agency (UK MHRA) in March 2018 and there were no critical or major observations cited, the pharma major said in a filing with the BSE.
Lupin MD Nilesh Gupta said: “the outcome of this inspection is a positive and encouraging sign for us, and is a testament to our commitment to maintain global manufacturing standards and best practices.” The approval is a significant development for the company’s Goa plant, the filing added.
